Squarepoint
AKRO

Squarepoint’s Akero Therapeutics AKRO Stock Holding History

Squarepoint’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,000
Closed -$445K – 4442
2025
Q1 		$445K Buy
+11,000
New +$466K ﹤0.01% 3415

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Squarepoint's AKRO Position: Q4 2025 in Review

Squarepoint sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 121,477 shares — an estimated $5.77M sold.

Squarepoint first reported a position in AKRO in Q3 2019 and held it in 14 quarters. The position peaked at $5.77M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Squarepoint reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 121,477 Akero Therapeutics shares in Q4 2025, an estimated $5.77M.
  • Squarepoint first reported a position in Akero Therapeutics in Q3 2019 and held it in 14 quarters.
  • Squarepoint's Akero Therapeutics position peaked at $5.77M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.